DrugMapper


Trade Names:	MONISTAT ORAVIG
Synonyms:	Conofite Dermazole Dumicoat Loramyc Micatin Miconazole Monistat Monistat-3 Monistat-Derm NSC-170986 Oravig Vusion
Status:	Approved (1974)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	A01AB09
UNII:	7NNO0D7S5M


InChI Key	BYBLEWFAAKGYCD-UHFFFAOYSA-N
Smile	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
InChI	InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H14Cl4N2O
Molecular Weight	416.14
AlogP	6.45
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	27.05
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	25.0

Action	Mechanism of Action	Reference
INHIBITOR	Cytochrome P450 51 inhibitor	PubMed PubMed PubMed PubMed Wikipedia

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 17 Cytochrome P450 family 17A Cytochrome P450 17A1	-	-	-	243	-
Enzyme Cytochrome P450 Cytochrome P450 family 19 Cytochrome P450 family 19A Cytochrome P450 19A1	400	600	-	-	-
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19	-	17900-18000	-	-	9
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4	-	180-851	-	-	-
Enzyme Cytochrome P450 Cytochrome P450 family 51 Cytochrome P450 family 51A Cytochrome P450 51A1	-	200	200	-	-
Enzyme Cytochrome P450	400	180-851	200	243	9
Enzyme Hydrolase	-	2400-21400	-	-	-
Enzyme Oxidoreductase	-	1400-6700	-	-	77
Enzyme	400	1400-6700	200	243	77
Ion channel Other ion channel Miscellaneous ion channel Ca2+ release-activated Ca2+ channel family	-	27000-100000	-	-	-
Ion channel Voltage-gated ion channel Voltage-gated calcium channel	-	3000	-	-	-
Membrane receptor Family C G protein-coupled receptor Small molecule receptor (family C GPCR) Neurotransmitter receptor (family C GPCR) Metabotropic glutamate receptor	-	6500	-	-	-
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	2000-3500	-	-	22
Unclassified protein	-	65000	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
HIV Infections	3	D015658	ClinicalTrials
Stomatitis	2	D013280	ClinicalTrials
Intertrigo	0	D007402	ClinicalTrials

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Salt

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Gastrointestinal disorders Gastrointestinal disorder	20.6
Infections and infestations Infection	17.1
Infections and infestations Infestation	17.1
Infections and infestations Infection	15.9
Infections and infestations Infestation	15.9
Nervous system disorders Nervous system disorder	13.1
Infections and infestations Infection	11.9
Infections and infestations Infestation	11.9
Nervous system disorders Nervous system disorder	10.6
Gastrointestinal disorders Diarrhoea	9.0
Blood and lymphatic system disorders Blood disorder	8.4
Nervous system disorders Nervous system disorder	8.4
Gastrointestinal disorders Diarrhoea	8.0
Gastrointestinal disorders Nausea	7.7
Nervous system disorders Headache	7.6
Blood and lymphatic system disorders Blood disorder	6.9
Nervous system disorders Headache	6.6
Gastrointestinal disorders Nausea	6.6
Gastrointestinal disorders Diarrhoea	6.0
Nervous system disorders Nervous system disorder	5.4
Nervous system disorders Headache	5.0
Gastrointestinal disorders Nausea	4.6
Gastrointestinal disorders Dysgeusia	4.1
Gastrointestinal disorders Vomiting	3.8
Gastrointestinal disorders Vomiting	3.1
Gastrointestinal disorders Dysgeusia	2.9
Gastrointestinal disorders Abdominal pain upper	2.8
Blood and lymphatic system disorders Anaemia	2.8
General disorders and administration site conditions Asthenia	2.8
Respiratory, thoracic and mediastinal disorders Cough	2.8
Gastrointestinal disorders Dry mouth	2.8
General disorders and administration site conditions Fatigue	2.8
Investigations Gamma-glutamyltransferase increased	2.8
Gastrointestinal disorders Gastroenteritis	2.8
General disorders and administration site conditions Pain	2.8
Gastrointestinal disorders Abdominal pain	2.7
Gastrointestinal disorders Gastrointestinal pain	2.7
Gastrointestinal disorders Nausea	2.7
Gastrointestinal disorders Oral discomfort	2.7
Gastrointestinal disorders Abdominal pain upper	2.5
Gastrointestinal disorders Vomiting	2.5
Gastrointestinal disorders Ageusia	2.4
General disorders and administration site conditions Pain	2.4
Infections and infestations Upper respiratory tract infection	2.4
General disorders and administration site conditions Asthenia	2.1
General disorders and administration site conditions Fatigue	2.1
Blood and lymphatic system disorders Lymphopenia	2.1
Blood and lymphatic system disorders Neutropenia	2.1
Infections and infestations Upper respiratory tract infection	2.1
Gastrointestinal disorders Abdominal pain	2.0
Gastrointestinal disorders Gastrointestinal pain	2.0
Gastrointestinal disorders Glossodynia	2.0
Musculoskeletal and connective tissue disorders Muscle spasms	2.0
Skin and subcutaneous tissue disorders Pruritus	2.0
Gastrointestinal disorders Vomiting	2.0
Gastrointestinal disorders Abdominal pain upper	1.7
Blood and lymphatic system disorders Anaemia	1.7
Respiratory, thoracic and mediastinal disorders Cough	1.7
Gastrointestinal disorders Dry mouth	1.7
Blood and lymphatic system disorders Lymphopenia	1.7
Gastrointestinal disorders Gastroenteritis	1.4
Nervous system disorders Nervous system disorder	1.4
Gastrointestinal disorders Oral discomfort	1.4
Nervous system disorders Headache	1.3
Investigations Gamma-glutamyltransferase increased	1.0
General disorders and administration site conditions Pain	1.0
Gastrointestinal disorders Nausea	0.7
Blood and lymphatic system disorders Neutropenia	0.7
General disorders and administration site conditions Pain	0.7
Skin and subcutaneous tissue disorders Pruritus	0.7
Gastrointestinal disorders Vomiting	0.7
Gastrointestinal disorders Ageusia	0.3

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Injury, poisoning and procedural complications	17.86
General disorders and administration site conditions	16.07
Gastrointestinal disorders	8.93
Blood and lymphatic system disorders	7.14
Reproductive system and breast disorders	7.14
Skin and subcutaneous tissue disorders	7.14
Immune system disorders	5.36
Infections and infestations	5.36
Renal and urinary disorders	5.36
Vascular disorders	5.36
Cardiac disorders	3.57
Investigations	3.57

Cross References

Resources	Reference
CAS NUMBER	22916-47-8
ChEBI	82892
ChEMBL	CHEMBL91
DrugBank	DB01110
DrugCentral	1800
EPA CompTox	DTXSID6023319
FDA SRS	7NNO0D7S5M
Human Metabolome Database	HMDB0015242
Guide to Pharmacology	2449
PharmGKB	PA450494
PubChem	4189
SureChEMBL	SCHEMBL2866

MICONAZOLE

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70